CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.
Bristol Myers Squibb (BMS) has agreed to acquire the global exclusive licensing rights to interleukin-12 (IL-12), an investigational immunotherapy programme from Dragonfly Therapeutics, in a deal worth more than $475m.
Biopharmaceutical company Gilead Sciences has expanded its strategic oncology collaboration with biotechnology company Tango Therapeutics.
This edition of the health sciences Journal is about hope and optimism, and how we must rethink our ways of working.
French drugmaker Sanofi has agreed to acquire late-stage biopharmaceutical company Principia Biopharma for an aggregate equity value of around $3.68bn.
UNION therapeutics announced the completion of an agreement with TFF Pharmaceuticals (TFF) to acquire an option to obtain a worldwide exclusive license for the use of their Thin Film Freezing technology in combination with niclosamide to focus on treatments for COVID-19.
GeneCentric Therapeutics has announced a research collaboration with Janssen Research & Development on RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC).
Bayer has agreed to acquire UK-based clinical-stage biotech company KaNDy Therapeutics for an upfront consideration of $425m.
Ligand Pharmaceuticals has agreed to acquire development and licencing biotechnology company Pfenex in a deal valued at around $516m.
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Seismic Bio, an immuno-oncology company focused on bispecific antibody development, today announced a partnership for the discovery and optimization of antibodies to high-value immuno-oncology targets.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.